コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 M) was associated with the highest uptake of yttrium.
2 njugates were 39 hr for indium and 46 hr for yttrium.
3 ositioned and automatically loaded with a 90-yttrium, 0.014-inch source wire that was 29 mm in length
5 rties both in solution and in vivo, and that yttrium-86 PET can be used to track the biodistribution
6 ull span of detection channels, ranging from yttrium (89 amu) to bismuth (209 amu), which are now ava
8 ment of hepatocellular carcinoma (HCC) using yttrium 90 ((90)Y) resin microsphere doses determined by
9 greement among CT, (99m)Tc-MAA SPECT/CT, and yttrium 90 ((90)Y) SPECT/CT or PET/CT was scored as opti
10 plantation, the use of radionuclides such as yttrium 90 (90Y) and copper 67 (67Cu), and the developme
11 valuation of the safety and effectiveness of yttrium 90 (90Y)-labeled anti-Id and shared Id (sId) MoA
12 ed with transarterial radioembolization with yttrium 90 in the Sorafenib versus Radioembolization in
13 survival when the beta-emitting radionuclide yttrium 90 instead of the alpha-emitting radionuclide (2
14 transarterial radioembolization (TARE) with yttrium 90 microspheres for liver-dominant metastatic co
16 tor of poor survival in patients who undergo yttrium 90 radioembolization for unresectable liver-domi
18 , handheld cannula containing a strontium 90/yttrium 90 source positioned over the active lesion.
19 he available data for radioembolization with yttrium 90 suggest that this is a potential new option f
20 des with high energy beta emissions, such as yttrium 90, and on strategies to optimize access of anti
21 ing beads, and radioembolization with use of yttrium 90, inflict lethal insult to tumors while preser
22 combined modality immunotherapy (CMIT) with yttrium (90)Y-DOTA-peptide-Lym-1 radioimmunotherapy (RIT
25 m the phase III First-Line Indolent Trial of yttrium-90 ((90)Y) -ibritumomab tiuxetan in advanced-sta
26 mography (DP-CBCT) achieved before and after Yttrium-90 ((90)Y) administration and to evaluate additi
27 (FL), to evaluate the safety and efficacy of yttrium-90 ((90)Y) ibritumomab tiuxetan given as consoli
28 study compares the novel radioimmunotherapy yttrium-90 ((90)Y) ibritumomab tiuxetan with a control i
29 atients who underwent radioembolization with yttrium-90 ((90)Y) microspheres prior to resection or tr
30 I trial evaluated the safety and efficacy of yttrium-90 ((90)Y)-ibritumomab tiuxetan in patients with
33 aluated the safety and efficacy of combining yttrium-90 (90Y) ibritumomab tiuxetan with high-dose car
35 eutic potential of the beta-emitting isotope yttrium-90 (t1/2, 64 hours) conjugated to the C6.5K-A di
36 udy was to assess the efficacy and safety of yttrium-90 (Y) radioembolization for treating hepatic me
38 dioactive micron-sized particles loaded with yttrium-90 (Y90) inside the blood vessels that supply a
42 8) to deplete peripheral blood B cells, then yttrium-90 ibritumomab tiuxetan (0.4 mCi/kg; maximum, 32
45 moembolization, transarterial chemoinfusion, yttrium-90 microsphere radioembolization, and sorafenib.
46 cted patients with hepatocellular carcinoma, yttrium-90 microsphere treatment is safe and well tolera
47 ized controlled trial is warranted comparing yttrium-90 microsphere treatment with transarterial chem
48 atients were selected from a database of 108 yttrium-90 microsphere-treated patients and were staged
55 ning first-line chemotherapy with SIRT using yttrium-90 resin microspheres in patients with metastati
56 tive internal radiation therapy (SIRT) using yttrium-90 resin microspheres to standard fluorouracil,
58 (SIR Spheres)--containing the beta-emitter, yttrium-90--into the arterial supply of the liver can ca
59 rated that 400 microCi (14.8 MBq) or more of yttrium-90-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetra
60 ty, tolerability, dosimetry, and efficacy of yttrium-90-labelled anti-CD22 epratuzumab tetraxetan ((9
61 ) by intra-arterial injection of radioactive yttrium-90-loaded microspheres is increasingly used for
71 sule opacification (PCO) and neodymium-doped yttrium aluminium garnet (Nd:YAG) capsulotomy rate of a
72 soliton-like pulse compression in a mm-long yttrium aluminium garnet crystal with no additional disp
73 negative effect of Nd: Yag (Neodymium-doped: Yttrium Aluminium Garnet) laser capsulotomy on the intra
74 Ce:YAG nanostructures (Ce:YAG = Cerium in Yttrium Aluminium Garnet), easy to control and shape, ha
75 rnet laser to be more efficient than holmium:yttrium-aluminium-garnet energy, but current erbium:yttr
83 through the performance of a neodymium-doped yttrium aluminum garnet (ND: YAG) laser capsulotomy with
84 n from a handheld Q-switched neodymium-doped yttrium aluminum garnet (Nd:YAG) laser pulse device used
85 A 532 nm frequency doubled neodymium-doped yttrium aluminum garnet (ND:YAG) laser was used to creat
88 lar lens (IOL) decentration, neodymium-doped yttrium aluminum garnet capsulotomy for posterior capsul
89 OL) was the most common (51.2%), followed by yttrium aluminum garnet capsulotomy, refractive surgery,
90 ration was stimulated in vivo with a Holmium:yttrium aluminum garnet laser (2.12 microm), free electr
93 derwent percutaneous Biosense-guided holmium:yttrium aluminum garnet LMR to areas of viable but ische
94 llow-emitting phosphor, such as cerium-doped yttrium aluminum garnet or (YAG):Ce(3+), coupled with a
96 copic therapy, including formalin, neodymium/yttrium aluminum garnet, argon and potassium titanyl pho
97 ping; carbon dioxide (CO2); and erbium-doped:yttrium, aluminum, and garnet (Er:YAG) laser techniques
98 itched, frequency-doubled Nd:YAG (neodymium, yttrium, aluminum, garnet) laser operating at 532 nm to
99 ith a single application of either an erbium:yttrium-aluminum-garnet (Er:YAG) (2,940-nm) laser or a d
100 ifferent photoablative dental lasers, erbium:yttrium-aluminum-garnet (Er:YAG) and diode, for the trea
102 ventional ultrasonic scaler versus an erbium:yttrium-aluminum-garnet (Er:YAG) laser on titanium surfa
103 ities including carbon dioxide (CO2), erbium:yttrium-aluminum-garnet (Er:YAG), pulsed dye (PDL), and
107 Animals then underwent TMR with a holmium:yttrium-aluminum-garnet (holmium:YAG) laser (n = 5), TMI
110 r capsular opacification and neodymium-doped yttrium-aluminum-garnet (YAG) laser capsulotomy, and sur
111 Medicare beneficiary proximity to his or her yttrium-aluminum-garnet (YAG) laser capsulotomy-providin
113 silluminator, 488-nm argon-ion laser, 532-nm yttrium-aluminum-garnet (YAG) laser, blue fluorescent li
114 trials of alternative devices using holmium:yttrium-aluminum-garnet and eximer lasers are underway.
115 ery, 35.6% of patients underwent a neodymium:yttrium-aluminum-garnet capsulotomy in the iMics1 NY-60
116 significant difference in PCO and neodymium:yttrium-aluminum-garnet capsulotomy rate 3 years after s
118 s (57.9%), 9 eyes (47.4%) required neodymium-yttrium-aluminum-garnet capsulotomy, and 3 eyes (15.8%)
119 ave demonstrated that a Q-switched neodymium:yttrium-aluminum-garnet dermatology laser kills larval m
120 lculated the modulation transfer function of yttrium-aluminum-garnet doped with cerium, anthracene, a
122 tle evidence that using a diode or neodymium:yttrium-aluminum-garnet laser adds clinical value over a
123 he introduction of the side-firing neodymium:yttrium-aluminum-garnet laser in the early 1990s laser p
124 er-diameter optic fiber coupled to a holmium:yttrium-aluminum-garnet laser or a 400-micrometer-diamet
125 t, including thermal ablation with neodymium:yttrium-aluminum-garnet laser, argon plasma coagulation,
127 the combination of carbon dioxide and erbium:yttrium-aluminum-garnet lasers to achieve improved resul
130 chial amyloidosis required Nd:YAG (neodymium:yttrium-aluminum-garnet) laser therapy for obstructive s
132 3)/K reduction system was used to synthesize yttrium analogues of 2 and 3, {[(Me(3)Si)(2)N](2)(THF)Y}
133 cage complexes, and their doped diamagnetic yttrium analogues, in which competing relaxation pathway
134 d trivalent rare earth metal ions containing yttrium and all naturally abundant lanthanide metals are
136 N(3), synthesized by direct reaction between yttrium and nitrogen at 78-125 GPa and 2500 K in laser-h
138 tly faster than CHX-A' without releasing the yttrium and showed the lowest uptake by bone of any of t
139 earth (RE) elements, which include scandium, yttrium and the series of fifteen lanthanides are an int
140 d after membrane modification with RBS using yttrium and tungstate ions (Y(3+) and WO4(2-)) as ion pr
141 coordination and radiochemical properties of yttrium, and its role in drugs for radiotherapy, PET ima
142 tent (defined as the sum of the lanthanides, yttrium, and scandium) for ashes derived from Appalachia
144 liquid speciation and the local structure of yttrium are studied in high-sulfate aqueous solutions, b
145 arsinidene complexes are described, and the yttrium-arsenic bonding is analyzed by density functiona
151 matic N-heterocycle mediated by scandium and yttrium benzyl complexes supported by a ferrocene 1,1'-d
152 gnized as forming very stable complexes with yttrium but also limited in usage because of slow Y(III)
154 y (DFT) methods are employed to examine this yttrium carbide cluster in certain family members, Y(2)C
155 iled study on the size and shape of isolated yttrium carbide clusters in different fullerene cages.
157 ive polymerization of the racemic monomer by yttrium catalysts bearing tetradentate ligands is report
159 its enantiomeric binding generality, binding yttrium chelates in both Lambda(deltadeltadeltadelta) an
161 e (2) with pendent donor groups as potential yttrium chelators for radioimmunotherapy (RIT) have been
162 strating a large reduction in bone-deposited yttrium, compared with (90)Y-hLL2 agents prepared with o
164 rically pure but different monomers using an yttrium complex as initiator proceeds readily at room te
165 amics of alkene binding to the primary alkyl yttrium complex Cp(2)YCH(2)CH(2)CH(CH(3))(2) (2) depend
166 onal for reproduction of the geometry of the yttrium complex was validated by comparison with the exp
167 of NO by the recently discovered (N(2))(3-) yttrium complex {[(Me(3)Si)(2)N](2)(THF)Y}(2)(micro(3)-e
170 ing in situ between the oxidized and reduced yttrium complexes resulted in a change in the rate of po
171 t-generation high temperature microreactors, yttrium dihydride (YH(2)) is an attractive solid state n
173 Li vacancy is oxidized for both pure LZO and yttrium-doped LZO, which leads to a small-polaron hole.
174 ion and relithiation were achieved within an yttrium-doped LZO/carbon composite cathode that exhibite
177 tructures of antibody 2D12.5 Fab bound to an yttrium-DOTA analogue and separately to a gadolinium-DOT
178 onoclonal antibody (mAb) 2D12.5 specific for yttrium-DOTA, and the chase was Y-DOTA-human transferrin
179 silver, tungsten, heavy rare earth elements (yttrium, europium, gadolinium, terbium, dysprosium, holm
182 , YH(9) was found to be the hydrogen-richest yttrium hydride in the studied pressure and temperature
183 hase diversity, variable hydrogen content in yttrium hydrides, and their metallic nature, as revealed
184 Here, we report a comprehensive study of the yttrium-hydrogen system with the highest predicted T(c)s
185 antibodies, (131)iodine-tositumomab and (90)yttrium-ibritumomab tiuxetan, were FDA-approved more tha
187 eport on a multicenter phase II trial of (90)yttrium-ibritumomab-tiuxetan ((90)YIT) as first-line sta
189 A mixed-ligand phthalocyanine/porphyrin yttrium(III) radical double-decker complex (DD) was synt
190 ally relevant radiometals, actinium(III) and yttrium(III), and probe their chemistry, using the recen
191 nalogous synthetic method was attempted with yttrium in arene solvents, the previously characterized
192 for statistical differences in the uptake of yttrium in bone and washed bone when either the DOTA or
193 roduct, 2IT-BAD-Lym-1, was labeled in excess yttrium in various buffers over a range of concentration
194 rene microbeads encoded with seven elements (yttrium, indium, and bismuth in addition to the four lan
198 ifferent Pt concentrations were deposited on yttrium iron garnet (YIG) films coated gadolinium galliu
199 spin Seebeck effect (LSSE) in the classic Pt/yttrium iron garnet (YIG) system and its association wit
203 can drive domain-wall motion in the Bi-doped yttrium iron garnet channel device by means of magnon sp
205 g all the possible materials, single-crystal yttrium iron garnet has shown up recently as a promising
206 he structure of the multilayer assemblies of yttrium iron garnet nanoparticles (YIG) with polyelectro
207 indicator composed of a bismuth-substituted yttrium iron garnet thin film, and visualizes the magnet
208 ) propagating in a 54 nm thick, 100 mum wide yttrium iron garnet waveguide grown epitaxially on a gar
209 n wave absorber is demonstrated comprising a yttrium iron garnet waveguide partially covered by gold.
210 si-shaped magnonic majority gate composed of yttrium iron garnet with a partially metallized surface.
212 a temperature gradient across a thin film of yttrium iron garnet, an insulating ferrimagnet, and form
218 s is extended through the array of available yttrium isotopes to enable roles for (90)Y complexes as
219 cer were treated with repeated cycles of (90)yttrium-labeled tetraazacyclododecane-tetraacetic acid m
220 ds CHX-B" and CHX-B' were not acceptable for yttrium labeling of antibody because of their high and p
221 e structure in which the host atom (calcium, yttrium, lanthanum) is at the centre of a cage formed by
224 enerating the second harmonic of a neodymium-yttrium-lithium-fluoride laser at a wavelength of 527 na
227 details the selective synthesis of different yttrium manganese oxides through assisted metathesis rea
230 R2* measurements of the 2% SPIO-labeled yttrium microsphere concentration were well correlated w
231 R2*-based measurements of 2% SPIO-labeled yttrium microsphere delivery were well correlated with i
232 , efficacy, and prognostic factors for (90)Y-yttrium microsphere radioembolization of unresectable li
235 doses of 5, 10, 15, or 20 mg 2% SPIO-labeled yttrium microspheres were infused into 24 rats (six rats
237 hanges in the electronic environment at each yttrium nuclide in the (Y(3)N)(6+) cluster (more than 20
240 ted wastewaters containing varying levels of yttrium or europium (10, 50, and 100 ppm), and the extra
241 present the synthesis of the first terminal yttrium organophosphinidene complex, Tp(tBu,Me)Y(=PC(6)H
242 ferroelectricity in epitaxial thin films of yttrium orthoferrite, YFeO(3), a perovskite-structured c
243 erfine transition of europium ion dopants in yttrium orthosilicate ((151)Eu(3+):Y2SiO5) using optical
244 PET scanner uses 4.2 x 6.3 x 30 mm lutetium yttrium orthosilicate (LYSO) crystals grouped in 9 x 6 b
245 odules each with 3 x 4 cerium-doped lutetium yttrium orthosilicate crystal blocks, each consisting of
247 ed readout of polished multicrystal lutetium yttrium orthosilicate scintillator arrays directly coupl
248 nium orthosilicate and cerium-doped lutetium-yttrium orthosilicate) that give VISTA machines a DOI co
250 sducer using trivalent ytterbium-171 ions in yttrium orthovanadate coupled to a nanophotonic waveguid
251 )Yb(3+) qubit doped into a nuclear-spin-rich yttrium orthovanadate crystal(15), we develop a robust q
253 eport the implementation of amorphous indium yttrium oxide (a-IYO) as a thin-film transistor (TFT) se
254 ssay used europium-doped streptavidin-coated yttrium oxide (YO(x)) or polystyrene (PS) microspheres t
255 m-thick amorphous film of tantalum oxide and yttrium oxide with an yttrium-to-tantalum atomic fractio
256 ly in relation to the unique, finer trigonal yttrium oxides produced during the additive manufacturin
257 hrough a porous matrix containing copper and yttrium oxides to subsequently act as catalytic sites fo
259 lts from a new PET/CT scanner using lutetium-yttrium oxyorthosilicate (LYSO) crystals for the PET com
260 ional scanner with the scintillator lutetium-yttrium oxyorthosilicate and a system timing resolution
261 and comprises 180 blocks of 13 x 13 lutetium yttrium oxyorthosilicate crystals (1.24 x 1.4 x 9.5 mm(3
262 layer-offset arrays of cerium-doped lutetium-yttrium oxyorthosilicate crystals read out by silicon ph
264 m the phenyl ring to the pyridine ring of an yttrium pyridyl complex supported by a 1,1'-ferrocene di
265 stem showed the opposite behavior to that of yttrium, revealing a metal-based dependency on the rate
267 metals (Ni, Co, Zn), rare earth elements and yttrium (REY), Fe (delta(56)Fe) and Ni (delta(60)Ni) iso
269 peutic efficacy of (131)I-IMP-R4-RS7 and (90)yttrium-RS7 were equivalent, and both agents yielded sig
271 alyst (metallic Co nanoparticles anchored on yttrium ruthenate pyrochlore oxide) is provided for secu
272 e demonstrate that the A-site substituent in yttrium ruthenium pyrochlores Y(1.8)M(0.2)Ru(2)O(7-delta
275 rmed to evaluate the proposed mechanism of a yttrium-salen complex-catalyzed acylation of secondary a
277 surgical use of the erbium, chromium-doped: yttrium, scandium, gallium, and garnet (Er,Cr:YSGG) lase
279 f lasers, most recently the erbium, chromium:yttrium-scandium-gallium-garnet (Er,Cr:YSGG) laser.
281 d by high-temperature sintering of compacted yttrium silicate powders doped with Pr(3+) and Li(+).
285 ithium disilicate [LD]) and a dense sintered yttrium-stabilized zirconia (YZ) were obtained from the
286 ved by supporting the CeO(2) thin film on an yttrium-stabilized zirconia substrate using a simulated
287 mics density functional theory models of the yttrium sulfate solution show that the YSO(4)(+) ion pai
288 CHX-B' were not acceptable for labeling with yttrium, the CHX-A' and CHX-A" were suitable, indicating
289 of tantalum oxide and yttrium oxide with an yttrium-to-tantalum atomic fraction of 14% was prepared
290 ted by seawater-like rare-earth element plus yttrium trace element signatures of the metacarbonates,
291 We report the reductive coupling of NO by an yttrium-tricopper complex generating a trans-hyponitrite
292 is of 5-amino-4-carboxamidothiazoles 1 by an yttrium-triflate-catalyzed reaction of thiocarboxylic ac
293 acids known to enhance isotacticity, such as yttrium trifluoromethanesulfonate (Y(OTf)(3)) and ytterb
295 ifferences manifested as significantly lower yttrium uptake in bone and cortical bone over a 10-d per
298 mium (Pr), neodymium (Nd), samarium (Sm), or yttrium (Y)] into an epitaxial strontium titanate oxide
299 d radiometal trap for a radiolabeled ligand (yttrium[Y]-DOTA) captured by a very high-affinity anti-Y